The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Open accessAbstract
Glucocorticoid hormones were discovered to have use as potent anti-inflammatory and immunosuppressive therapeutics in the 1940s and their continued use and development have successfully revolutionized the management of acute and chronic inflammatory diseases. However, long-term use of glucocorticoids is severely hampered by undesirable metabolic complications, including the development of type 2 diabetes mellitus. These effects occur due to glucocorticoid receptor activation within multiple tissues, which results in inter-organ crosstalk that increases hepatic glucose production and inhibits peripheral glucose uptake. Despite the high prevalence of glucocorticoid-induced hyperglycaemia associated with their routine clinical use, treatment protocols for optimal management of the metabolic adverse effects are lacking or underutilized. The type, dose and potency of the glucocorticoid administered dictates the choice of hypoglycaemic intervention (non-insulin or insulin therapy) that should be provided to patients. The longstanding quest to identify dissociated glucocorticoid receptor agonists to separate the hyperglycaemic complications of glucocorticoids from their therapeutically beneficial anti-inflammatory effects is ongoing, with selective glucocorticoid receptor modulators in clinical testing. Promising areas of preclinical research include new mechanisms to disrupt glucocorticoid signalling in a tissue-selective manner and the identification of novel targets that can selectively dissociate the effects of glucocorticoids. These research arms share the ultimate goal of achieving the anti-inflammatory actions of glucocorticoids without the metabolic consequences. Glucocorticoid therapies are widely used to treat acute and chronic inflammatory diseases, yet these drugs induce adverse metabolic effects. This Review highlights new insights into mechanisms of glucocorticoid-induced diabetes mellitus and discusses current and future therapeutic options. Glucocorticoid drugs are widely prescribed to treat inflammatory diseases and to prevent organ transplant rejection yet they promote hyperglycaemia and diabetes mellitus. Glucocorticoid-induced hyperglycaemia manifests directly via glucocorticoid signalling in metabolic organs and tissues (liver, adipose tissue, muscle, bone and pancreatic β-cells) and indirectly via inter-organ hormone and metabolite flux. No single consensus exists with respect to optimal screening frequency for glucocorticoid-induced hyperglycaemia due to context-dependent factors, although analysis of postprandial glucose (not fasting glucose) is recommended. Hypoglycaemic agents (such as insulin sensitizers and insulin) can provide satisfactory glucose control but need to be tailored for differences in the dose and type of glucocorticoid used. Developing selective glucocorticoid modulators that dissociate the diabetogenic from the anti-inflammatory effects of glucocorticoids continues to be challenging; however, new pharmacological targets that prevent diabetogenic effects are on the horizon. Glucocorticoid drugs are widely prescribed to treat inflammatory diseases and to prevent organ transplant rejection yet they promote hyperglycaemia and diabetes mellitus. Glucocorticoid-induced hyperglycaemia manifests directly via glucocorticoid signalling in metabolic organs and tissues (liver, adipose tissue, muscle, bone and pancreatic β-cells) and indirectly via inter-organ hormone and metabolite flux. No single consensus exists with respect to optimal screening frequency for glucocorticoid-induced hyperglycaemia due to context-dependent factors, although analysis of postprandial glucose (not fasting glucose) is recommended. Hypoglycaemic agents (such as insulin sensitizers and insulin) can provide satisfactory glucose control but need to be tailored for differences in the dose and type of glucocorticoid used. Developing selective glucocorticoid modulators that dissociate the diabetogenic from the anti-inflammatory effects of glucocorticoids continues to be challenging; however, new pharmacological targets that prevent diabetogenic effects are on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Sapolsky, R. M., Romero, L. M., & Munck, A. U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0389 · Cited by 7,541
Sapolsky, R. M. (2000) · Endocrine Reviews · doi:10.1210/er.21.1.55 · Cited by 7,533
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Stöckl, S., Göttl, C., Grifka, J., & Grässel, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350089 · Cited by 4,656
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Endocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554
Cited by
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 268
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
Metadata
- Authors
- Li, J.-X., & Cummins, C. L.
- Venue
- Nature Reviews Endocrinology
- Published
- 2022-05-18
- Volume
- 18
- Issue
- 9
- Pages
- 540-557
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4280598314
- Cited by
- 257
- References
- 223
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. https://app.cochat.ai/papers/10.1038/s41574-022-00683-6
- The paper
- Li, J.-X., & Cummins, C. L. (2022). Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00683-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.